IMV Inc. (IMVIQ)
| Market Cap | 604.90K |
| Revenue (ttm) | 240,146 |
| Net Income (ttm) | -27.73M |
| Shares Out | 8.34M |
| EPS (ttm) | -3.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 0.0725 |
| Day's Range | n/a |
| 52-Week Range | 0.0002 - 0.5000 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About IMVIQ
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE... [Read more]
Financial Performance
In 2022, IMV Inc.'s revenue was 329,000, an increase of 75.00% compared to the previous year's 188,000. Losses were -37.99 million, 3.83% more than in 2021.
Financial numbers in CAD Financial StatementsNews
IMV Receives NASDAQ Delisting Notice
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (the “Company” or “IMV”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educa...
Horizon Technology Finance Announces First Quarter 2023 Financial Results
- First Quarter 2023 Net Investment Income per Share of $0.46; NAV per Share of $11.34 - - Debt Portfolio Yield of 16.3% - - Grew Portfolio Year over Year by 39% to $715 Million - - Horizon Platform E...
IMV Initiates Restructuring Proceedings Under the CCAA to Complete the Review of its Strategic Alternatives
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #CancerVaccine--IMV Inc. (the “Company” or “IMV”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical Company developing a p...
IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #CancerVaccine--IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune...
IMV Inc. Announces Changes to Its Board of Directors
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #CancerVaccine--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, bas...
IMV Inc. Announces Strategic Update as well as Fourth Quarter and Full Year 2022 Financial and Operational Results
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #CancerVaccine--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune...
IMV Inc. to Announce Fourth Quarter and Fiscal Year 2022 Results and Host a Conference Call and Webcast on March 16, 2023
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #CancerVaccine--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, bas...
IMV Inc. Presents Positive Initial Results From The MVP-S Phase 2B VITALIZE Trial
DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #CancerVaccine--IMV Inc.
IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S
DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of immune-ed...
IMV Announces Closing of US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company advancing a portfolio of therapies b...
IMV Announces US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company advancing a portfolio of therapies b...
IMV Inc. Announces Initial Data from the Ongoing Phase 2B VITALIZE Trial in Patients with r/r DLBCL
DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of immune-ed...
IMV Commences Trading on the TSX and Nasdaq Post-Reverse Stock Split
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (the “Corporation” or “IMV”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune...
IMV Shareholders Approve Reverse Stock Split at 88%
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (the “Corporation”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educatin...
IMV Receives Nasdaq Notification Regarding Market Value of Listed Securities
DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies ...
IMV Inc. Announces Third Quarter 2022 Financial and Operational Results
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies ba...
IMV Inc. to Announce Third Quarter 2022 Results and Host a Conference Call and Webcast on November 11, 2022
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.
IMV Provides an Update on The VITALIZE Trial
DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-ed...
IMV Inc. Announces Strategic Reorganization
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of immune-educa...
IMV Inc. to Present at Two Investor Conferences in September
DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies ...
IMV Inc. Announces Second Quarter 2022 Financial and Operational Results
DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing...
IMV Re-Establishes Its At-the-Market Facility Under Renewed Base Shelf Prospectus
DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (“IMV” or the “Company”) (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of im...
IMV Inc. to Announce Second Quarter 2022 Results and Host a Conference Call and Webcast on August 11, 2022
DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of im...
Horizon Technology Finance Provides Second Quarter 2022 Portfolio Update
- Horizon Platform Originates Record $192 Million of New Loans in Q2, Including $137 Million of New Loans for HRZN - - Horizon Platform Ends Quarter with Record Committed Backlog of $267 Mill...
IMV Announces Annual and Special Meeting of Shareholders Voting Results
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies bas...